|
Module home
Module introduction
Module information
Related articles: Advances in
Psychiatric Treatment
About the authors
Pre-module test
Section 1: Introduction and
epidemiology
(1.1) Section 1: Introduction and epidemiology
(1.2) Introduction and epidemiology
(1.3) Introduction and epidemiology
(1.4) Reflection
(1.5) Epidemiology of stimulant misuse
(1.6) Epidemiology of stimulant misuse
(1.7) Section 1: Recap
(1.8) Section 1:
Summary
Section 2: Cocaine and crack
cocaine
(2.1) Section 2: Cocaine and crack cocaine
(2.2) Difference between cocaine and crack cocaine
(2.3) Cocaine: misuse among the general population
(2.4) Cocaine: misuse among the general population
(2.5) Pause for thought
(2.6) Pause for thought: answer
(2.7) Crack cocaine: misuse among the general population
(2.8) Cocaine: misuse among young adults
(2.9) Patterns of use and socio-demographics
(2.10) Profiles of cocaine users
(2.11) Treatment demand indicator
(2.12) Treatment demand indicator
(2.13) Reflection
(2.14) Reflection: answer
(2.15) Cocaine-related deaths
(2.16) Cocaine-related deaths
(2.17) Section 2: Recap
(2.18) Section 2:
Summary
Section 3:
Amphetamine, methamphetamine and ecstasy
(3.1) Section 3: Amphetamine, methamphetamine
and ecstasy
(3.2) Definitions
(3.3) Definitions
(3.4) Amphetamine, methamphetamine and
ecstasy: misuse among the
general population
(3.5) Amphetamine and methamphetamine: misuse
among the general population
(3.6) Amphetamine and methamphetamine: misuse
among the general population
(3.7) Amphetamine and methamphetamine: misuse
among the general population
(3.8) Amphetamine and methamphetamine: misuse
among young adults
(3.9) Amphetamine and methamphetamine:
treatment demand indicator
(3.10) Amphetamine- and
methamphetamine-related deaths
(3.11) Ecstasy: misuse among the general population
(3.12) Ecstasy: misuse among the general population
(3.13) Pause for thought
(3.14) Pause for thought: answer
(3.15) Ecstasy: misuse among young adults
(3.16) Ecstasy: patterns of use
(3.17) Ecstasy: treatment demand indicator
(3.18) Ecstasy-related deaths
(3.19) Section 3: Recap
(3.20) Section 3:
Summary
Section 4: Novel psychoactive drugs,
research chemicals and
‘legal highs’
(4.1) Section 4: Novel psychoactive drugs,
research chemicals and ‘legal highs’
(4.2) Novel psychoactive drugs, research
chemicals and ‘legal highs’
(4.3) Novel psychoactive drugs, research
chemicals and ‘legal highs’
(4.4) BZP and piperazine derivatives
(4.5) Mephedrone and cathinone derivatives
(4.6) Mephedrone and cathinone derivatives
(4.7) Mephedrone-related deaths
(4.8) Naphyrone
(4.9) Section 4: Recap
(4.10) Section
4: Summary
Section 5: Stimulant misuse: impact on mental
health
(5.1) Section 5: Stimulant misuse: impact on mental
health
(5.2) Introduction
(5.3) Dual diagnosis
(5.4) Dual diagnosis
(5.5) Substance-induced psychiatric
disorders
(5.6) Substance-induced psychiatric
disorders
(5.7) Cocaine: impact on mental health
(5.8) Cocaine: impact on mental health
(5.9) Cocaine: clinical vignette
(5.10) Amphetamines: impact on mental
health
(5.11) Amphetamines: impact on mental
health
(5.12) Psychopathological consequences
(5.13) Clinical signs of amphetamine
intoxication
(5.14) Amphetamine-induced psychosis
(5.15) Amphetamine withdrawal symptoms
(5.16) Amphetamine neurotoxicity
(5.17) Amphetamine: clinical vignette
(5.18) Ecstasy: impact on mental health
(5.19) Psychoactive effects
(5.20) Neurocognitive problems
(5.21) Impact on serotonin levels
(5.22) Impact on serotonin levels
(5.23) Acute and long-term consequences
(5.24) Ecstasy: clinical vignette
(5.25) Mephedrone: impact on mental health
(5.26) Mephedrone: impact on mental health
(5.27) Mephedrone: clinical vignette
(5.28) Section 5: Recap
(5.29) Section
5: Summary
Module summary
Module test
References
Further reading
Acknowledgements
Take-home notes
Send feedback
Appendix
(5.9) Transcript: cocaine – clinical vignette
(5.17) Transcript: amphetamine – clinical vignette
(5.24) Transcript: ecstasy – clinical vignette
|